Exon skipping therapies market seen reaching $5.9 billion by 2030

By AI, Created 4:49 PM UTC, May 18, 2026, /AGP/ – The exon skipping therapies market is projected to rise from $2.34 billion in 2025 to about $5.9 billion by 2030, driven by genetic testing, rare disease research and broader use of RNA-based treatments. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Exon skipping therapies aim to treat genetic diseases at the RNA level, which could expand options for patients with rare inherited disorders. - The market’s projected growth signals rising demand for targeted genetic medicine and the tools needed to deliver it. - Better newborn screening and genetic testing are making more patients visible to the healthcare system earlier.

What happened: - The Business Research Company projected the exon skipping therapies market will grow from $2.34 billion in 2025 to $2.81 billion in 2026. - The market is forecast to reach $5.89 billion by 2030, with a 20.4% compound annual growth rate. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period.

The details: - Exon skipping therapies alter pre-mRNA splicing to exclude disease-causing exons. - The approach uses antisense oligonucleotides that bind to targeted pre-mRNA sequences and help skip mutated exons during RNA processing. - The result is shorter proteins that can still retain partial function. - Historical growth was supported by higher Duchenne muscular dystrophy prevalence, advances in RNA splicing research, early approvals for antisense therapies, more rare disease funding and more biotechnology partnerships. - Forecast growth is expected to come from personalized genetic medicine, a larger pipeline of exon-targeted therapies, investment in delivery technologies, broader approvals for inherited neuromuscular disorders and deeper partnerships between research institutions and biopharma companies. - The report highlighted continued work in antisense oligonucleotide chemistry, combination genetic therapies, RNA-based therapeutics and clinical trials focused on exon-specific mutations. - The report covered Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also published a free sample report and the full exon skipping therapies market report.

Between the lines: - The market outlook reflects a broader shift toward precision medicine for conditions that have had limited treatment options. - The NHS launched a newborn screening program in October 2024 that tested hundreds of newborns for more than 200 rare genetic conditions, with plans to expand screening to as many as 100,000 babies across England. - More screening tends to increase diagnosis rates, which can expand the pool of patients eligible for exon skipping therapies.

What’s next: - Market growth will likely depend on whether drug developers can improve delivery technologies and move more exon-targeted therapies through regulation. - Expansion in genetic testing and newborn screening could continue to lift diagnosis rates for rare disorders. - More clinical trials and partnerships may determine how quickly exon skipping therapies reach broader inherited disease markets.